Lakefront Biotherapeutics (LKFT) Common Equity (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Common Equity for 13 consecutive years, with $3.7 billion the latest figure, recorded in Q1 2026.

• Quarterly Common Equity rose 18.39% year-over-year to $3.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 billion (up 18.39% YoY) and the FY2025 annual result came in at $3.7 billion, up 11.7% from the prior year.
• Common Equity grew to $3.7 billion in Q1 2026 per LKFT's latest filing, from $3.7 billion in the prior quarter.
• Over the last five years, Common Equity for LKFT reached as high as $3.7 billion in Q1 2026 and fell as low as $2.8 billion in Q3 2025.
• A 5-year average of $3.2 billion and a median of $3.1 billion in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2025 — Common Equity fell 14.52% — and 2026, when it increased 18.39%.
• Year by year, Common Equity stood at $2.9 billion in 2022, then increased by 10.67% to $3.2 billion in 2023, then gained by 3.63% to $3.3 billion in 2024, then grew by 11.7% to $3.7 billion in 2025, then rose by 0.54% to $3.7 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $3.7 billion, $3.7 billion, and $2.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.